The HOPE investigators assigned 9297 patients aged 55 years or older and at high risk of stroke to either ramipril or placebo, and followed them at 6-month intervals for an average of 4.5 years.

FDA approves new ramipril indication: for the reduction of MI, stroke, and death Katherine Rother October 12, 2000 0 Thu, 12 Oct 2000 20:59:09 ...